Skip to main content
SpringerLink
Log in

Autologous Transplantation for Hodgkin’s Disease

Who Benefits?

  • Chapter
Current Controversies in Bone Marrow Transplantation

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

The majority of patients with Hodgkin’s disease (HD) can be cured with radiation therapy (RT) and/or combination chemotherapy (CT). However, patients who relapse after attaining a complete remission (CR) from CT, and those who fail to achieve a complete response with CT (primary refractory disease), have a poor outcome using conventional-dose second-line or salvage regimens (1–3). Over the past 15 yr, numerous clinical trials using high-dose chemotherapy (HDCT), or chemoradiotherapy, with autologous stem cell transplantation (ASCT) have been reported, and 30–50% of patients appear to be cured using this approach. These results compare favorably with historical data using conventional second-line chemoradiotherapy, and, currently, ASCT is the salvage treatment of choice for many patients with relapsed and primary refractory HD (4–7).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD, J. Clin. Oncol., 15 (1997) 528–534.

    PubMed  CAS  Google Scholar 

  2. Longo D, Duffey P, Young R, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure, J. Clin. Oncol., 10 (1992) 210–218.

    PubMed  CAS  Google Scholar 

  3. Yahalom J. Management of relapsed and refractory Hodgkin’s disease, Semin. Radiat. Oncol., 6 (1996) 210–224.

    Article  PubMed  Google Scholar 

  4. Bierman PJ and Armitage JO. Role of autotransplantation in Hodgkin’s disease, Hematol. Oncol. Clin. North Am., 7 (1993) 591–611.

    PubMed  CAS  Google Scholar 

  5. Goldstone AH, McMillan AK: Place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin’s disease, Ann. Oncol., 4 (1993) 21–27.

    PubMed  Google Scholar 

  6. Armitage JO, Bierman PJ, Vose JM, et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin’s disease, Am. J. Med., 91 (1991) 605–611.

    Article  PubMed  CAS  Google Scholar 

  7. Carella AM, Congiu AM, Gaozza E, et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin’s disease patients: an Italian study group report, J. Clin. Oncol., 6 (1988) 1411–1416.

    PubMed  CAS  Google Scholar 

  8. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial, Lancet, 341 (1993) 1051–1054.

    Article  PubMed  CAS  Google Scholar 

  9. Schmitz N, Sextro M, Hasenclever D, et al. HD-R1:First results of a randomized trial comparing aggressive chemotherapy with high-dose therapy (HDT) and hematopoietic and stem cell transplantation (HSCT) in patients with chemosensitive relapse of Hodgkin’ s disease, Blood,90 (Suppl 1) (1997) 115a(Abstract).

    Google Scholar 

  10. Sweetenham JW, Taghipour G, Milligan D, et al. High-dose therapy and ASCT for patients with HD in first relapse after chemotherapy: results from the EBMT, Bone Marrow Transplant., 20 (1997) 745–752.

    Article  PubMed  CAS  Google Scholar 

  11. Yahalom J, Gulati SC, Toia M, et al. Accelerated hyperfractionated total lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin’s disease, J. Clin. Oncol., 11 (1993) 1062–1070.

    PubMed  CAS  Google Scholar 

  12. Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease, Blood, 89 (1997) 814–822.

    PubMed  CAS  Google Scholar 

  13. Schmitz N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilized PBPCT vs. ABMT in lymphoma patients, Lancet, 347 (1996) 353–357.

    Article  PubMed  CAS  Google Scholar 

  14. Moskowitz CH, Glassman JR, Wuest D, et al. Factors affecting mobilization of PBPCs in patients with lymphoma, Clin. Cancer Res.,4 (19) 311–316.

    Google Scholar 

  15. Jagannath S, Armitage JO, Dicke KA, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin’s disease, J. Clin. Oncol., 7 (1989) 179–185.

    PubMed  CAS  Google Scholar 

  16. Moormeier JA, Williams SF, Kammer LS, et al. Autologous bone marrow transplantation followed by involved field radiotherapy in patients with relapsed or refractory Hodgkin’s disease, Leukemia Lymphoma, 5 (1991) 243–246.

    Article  Google Scholar 

  17. Carella A, Carlier P, Congiu A, et al. Nine years’ experience with ABMT in 128 patients with Hodgkin’s disease: an Italian study group report, Leukemia, 5 (1991) 68–71.

    PubMed  Google Scholar 

  18. Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin’ s disease and non-Hodgkin’ s lymphoma. A dose-finding study, J. Clin. Oncol., 8 (1990) 648–856.

    PubMed  CAS  Google Scholar 

  19. Zulian GB, Selby P, Milan S, et al. High-dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin’s disease, Br. J. Cancer, 59 (1989) 631–635.

    Article  PubMed  CAS  Google Scholar 

  20. Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy, Blood, 83 (1994) 1193–1199.

    PubMed  CAS  Google Scholar 

  21. Poen JC, Hoppe RT, and Homing SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival, Inn. J. Radiat. Oncol. Biol. Phys., 36 (1996) 3–12.

    Article  CAS  Google Scholar 

  22. Wirth A, Cony J, Laidlaw C, et al. Salvage radiotherapy for Hodgkin’s disease following chemotherapy failure, Int. J. Radiat. Oncol. Biol. Phys., 39 (1997) 599–607.

    Article  PubMed  CAS  Google Scholar 

  23. Pezner RD, Lipsett JA, Vora N, et al. Radical radiotherapy as salvage treatment for relapse of Hodgkin’s disease initially treated by chemotherapy alone: prognostic significance of the disease-free interval, Int. J. Radiat. Oncol. Biol. Phys., 30 (1994) 965–970.

    Article  PubMed  CAS  Google Scholar 

  24. Biti G, Cimino G, Cartoni C, et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin’s disease: eight-year update of an Italian prospective randomized study, J. Clin. Oncol., 10 (1992) 378–382.

    PubMed  CAS  Google Scholar 

  25. Young R, Canellos G, Chabner B, et al. Patterns of relapse in advanced Hodgkin’s disease treated with combination chemotherapy, Cancer, 42 (1978) 1001–1007.

    Article  PubMed  CAS  Google Scholar 

  26. Yahalom J, Ryu J, Straus D, et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin’s disease treated with alternating chemotherapy combinations, J. Clin. Oncol.,9 (1991) 2193–2201.

    Google Scholar 

  27. Brizel D, Winer E, Prosnitz L, et al. Improved survival in advanced Hodgkin’s disease with the use of combined modality therapy, Int. J. Radian. Oncol. Biol. Phys., 19 (1991) 535–542.

    Article  Google Scholar 

  28. Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients, Blood, 81 (1993) 1137–1145.

    PubMed  CAS  Google Scholar 

  29. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience, J. Clin. Oncol.,11(1993) 23422350.

    Google Scholar 

  30. Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant, J. Clin. Oncol., 11 (1993) 704–711.

    PubMed  CAS  Google Scholar 

  31. Mundt AJ, Sibley G, Williamks S, et al. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin’s disease, Int. J. Radiat. Oncol. Biol. Phys., 33 (1995) 261–270.

    Article  PubMed  CAS  Google Scholar 

  32. Phillips GL, Wolff SN, Herzig RH, et al. Treatment of progressive Hodgkin’s disease with intensive chemoradiotherapy and autologous bone marrow transplantation, Blood, 73 (1989) 2086–2092.

    PubMed  CAS  Google Scholar 

  33. Gianni AM, Siena S, Bregni M, et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin’s disease, Ann. Oncol., 2 (1991) 645–653.

    PubMed  CAS  Google Scholar 

  34. McMillan A, and Goldstone A. What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin’s disease? Leukemia Res., 15 (1991) 237–243.

    Article  CAS  Google Scholar 

  35. Petersen FB, Appelbaum FR, Hill R, et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle, J. Clin. Oncol., 8 (1990) 638–647.

    PubMed  CAS  Google Scholar 

  36. Nadermanee A, O’Donnell MR, Snyder DS et al. High-dose chemotherapy with or without TBI followed by ASCT for patients with relapsed and refractory HD: results of 85 patients and analysis of prognostic factors, Blood, 85 (1995) 1381–1390.

    Google Scholar 

  37. Roach M, Kapp D, Rosenberg S, et al. Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin’s Disease, J. Clin. Oncol., 5 (1987) 550–555.

    PubMed  Google Scholar 

  38. Mauch P, Tarbell N, Skarin A, et al. Wide-field radiation therapy alone or with chemotherapy for Hodgkin’s disease in relapse from combination chemotherapy, J. Clin. Oncol., 5 (1987) 544–549.

    PubMed  CAS  Google Scholar 

  39. Gribben JG, Linch DC, Singer CR, et al. Successful treatment of refractory Hodgkin’s disease by high-dose combination chemotherapy and autologous bone marrow transplantation, Blood, 73 (1989) 340–344.

    PubMed  CAS  Google Scholar 

  40. Reece DE, Barnett MJ, Connors JM, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin’s disease [published erratum appears in J. Clin. Oncol. 10 (1992) 170], J. Clin. Oncol., 9 (1991) 1871–1879.

    PubMed  CAS  Google Scholar 

  41. Yahalom J. Integrating radiotherapy into bone marrow transplantation programs for HD, Int. J. Radiat. Oncol. Biol. Phys., 33 (1995) 525–528.

    Article  PubMed  CAS  Google Scholar 

  42. Yahalom J, Moni J, Gulati SC, et al. Salvage therapy of Hodgkin’s disease with intensive total lymphoid irradiation, cyclophosphamide and etoposide followed by autologous bone marrow transplantation: 10-year results, Proc. ASCO, 16 (1997) 24.

    Google Scholar 

  43. Moskowitz CH, Nimer SD, Portlock CS, et al. Ifosfamide, carboplatin, and etoposide (ICE) cytoreduction followed by high-dose chemoradiotherapy and ASCT for refractory and relapsed Hodgkin’s disease: an intent to treat study, Blood, 90 (Suppl 1) (1997) 233a.

    Google Scholar 

  44. Bierman PJ, Bagin RG, Jagannath S, et al. High-dose chemotherapy followed by ASCT in HD: longterm follow-up in 128 patients, Ann. Oncol., 4 (1993) 767–773.

    PubMed  CAS  Google Scholar 

  45. Horning SJ, Chao NJ, and Negrin RS. High-dose therapy and ASCT for recurrent or refractory HD: analysis of the Stanford University results and prognostic indices, Blood, 89 (1997) 801–813.

    PubMed  CAS  Google Scholar 

  46. Shipp MA, Harrington DP, Anderson JR, et al. Predictive model for aggressive NHL, N. Engl. J. Med., 329 (1993) 987–992.

    Article  Google Scholar 

  47. Gianni AM Bregni M, Sienna S, Brambilla C, et al. High-dose chemotherapy and ABMT compared with MACOP-B in aggressive B cell lymphoma, N. Engl. J. Med., 1290 (1997) 336–341.

    Google Scholar 

  48. Hansenclever D and Diehl V. Prognostic score for advanced HD, N. Engl. J. Med.,339 (1998) 15061514.

    Google Scholar 

  49. Barlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced stage Hodgkin’s disease, J. Clin. Oncology., 13 (1995) 1080–1088.

    Google Scholar 

  50. Moskowitz CH, Yahalom J, Straus D, et al. The use of Stanford V overcomes poor prognostic features in patients with advance stage HD, Blood, 92 (1998) 2579.

    Google Scholar 

  51. Tesch H, Diehl V, Lathan B, et al. Moderate dose escalation for advanced-stage Hodgkin’s disease using bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone scheme and adjuvant radiotherapy. A study of the German Hodgkin’s Lymphoma Study Group, Blood, 92 (1998) 4560–4567.

    PubMed  CAS  Google Scholar 

  52. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced stage Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD, N. Engl. J. Med., 327 (1992) 1478–1484.

    Article  PubMed  CAS  Google Scholar 

  53. Ahmed T, Lake DE, Beer M, et al. Single and double autotransplants for relapsing/refractory HD: results of two consecutive trials, Bone Marrow Transplant., 19 (1997) 449–454.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Craig H. Moskowitz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen D. Nimer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bone Marrow Transplant Program, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Brian J. Bolwell MD (Director, Staff Physician) (Director, Staff Physician)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Moskowitz, C.H., Nimer, S.D. (2000). Autologous Transplantation for Hodgkin’s Disease. In: Bolwell, B.J. (eds) Current Controversies in Bone Marrow Transplantation. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-657-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-657-7_10

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9812-7

  • Online ISBN: 978-1-59259-657-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation